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Abstract. This study was undertaken to investigate the susceptibility of rhesus monkeys to the calpox virus, an
orthopoxvirus (OPXV) of the Cowpox virus species (CPXV), which is uniformly lethal in common marmosets.
Six rhesus monkeys were either intravenously (i.v.) or intranasally (i.n.) exposed to the virus. Monitoring of the
macaques after viral exposure included physical examinations, the determination of viral load by real-time PCR
and plaque assay, and the analysis of humoral responses. Two i.v. inoculated animals developed numerous clas-
sical pox lesions that started after inoculation at days 7 and 10. Both animals became viremic and seroconverted.
They exhibited maximal numbers of lesions of approximately 50 and 140 by day 21. One animal completely
recovered, while the other one suffered from a phlegmonous inflammation of a leg initially induced by a secon-
darily infected pox lesion and was euthanized for animal welfare reasons. In contrast to previous pathogenicity
studies with the calpox virus in marmosets, none of the four animals inoculated intranasally with doses of the
calpox virus exceeding those used in marmosets by orders of magnitude showed typical clinical symptoms.
No viral DNA was detectable in the blood of those animals, but three animals seroconverted. In two of these
three animals, infectious virus was sporadically isolated from saliva. This indicates that rhesus monkeys are less
susceptible to calpox virus infection, which limits their use in further intervention studies with OPXV.
1 Introduction
The genus Orthopoxvirus (OPXV) comprises several species
including Variola virus (VARV), Monkeypox virus (MPXV),
Cowpox virus (CPXV) and Vaccinia virus (VACV) that
are all, more or less, pathogenic for humans. Fortunately,
the causative agent of smallpox, VARV, has successfully
been eradicated by a worldwide vaccination campaign led
by the World Health Organization (WHO) (Fenner, 1988;
World Health Organization, 1980). On the recommenda-
tion of the WHO, the vaccination program was stopped in
the 1980s because of severe side effects of the vaccine.
The number of people lacking immunity against smallpox
and other zoonotic OPXV infections is therefore increasing
(Shchelkunov, 2013). Consequently, a potential biowarfare
attack with smallpox would hit a nearly unprotected popula-
tion. In addition, the zoonotic potential of orthopoxviruses,
e.g., the increasing incidence of human monkeypox in the
Democratic Republic of the Congo (Rimoin et al., 2010), is
of a growing concern. The 2003 outbreak in the USA caused
by prairie dogs infected by imported exotic pets from Africa
clearly showed that monkeypox is not restricted to Africa and
can be transmitted at any time to any place (Centers for Dis-
ease, C. a. P., 2003; Reed et al., 2004). So far, no licensed
antiviral treatment for poxvirus infections is available. There
are two vaccines with irregular disposability. In the USA
the second generation vaccine ACAM2000® has been li-
censed since 2007 (http://www.fda.gov/ohrms/dockets/ac/
07/briefing/2007-4292b2-02.pdf), and Imvanex®, based on
the modified vaccinia virus Ankara, received a marketing
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authorization by the European Commission in 2013. Nev-
ertheless, in light of increasing numbers of zoonotic in-
fections with different orthopoxviruses new vaccines and
therapeutic agents are urgently needed. Both have to be
tested in adequate animal models. Since small animal mod-
els have considerable limitations regarding disease pathology
and pharmacokinetics, animal models with nonhuman pri-
mates (NHPs), the closest relatives to humans, are essential.
Over the last decades several animal models for OPXV
were developed in NHPs (Schmitt et al., 2014). Unfortu-
nately, none of the animal models fulfills all the criteria
needed and all have limitations (Hutson and Damon, 2010;
Safronetz et al., 2013). Based on the Food and Drug Admin-
istration animal efficacy rule, new drugs and vaccines must
be tested in more than one species and one of the species
should be a nonhuman primate animal model (Snoy, 2010).
The current nonhuman primate model for smallpox is the
intravenous (i.v.) inoculation of MPXV, which causes a ful-
minant disease with many similarities to that of the human
disease. A great disadvantage of the intravenous infection
route is that it does not mimic the natural route of smallpox
transmission, which occurs through close contact or inhaled
aerosols. Key events of a natural pox infection such as the
alteration of the upper respiratory tract, a primary viremic
phase and prodromal phases are skipped. Nevertheless, these
models cause a systemic disease with mortality rates of up to
100 % and can be used to evaluate the efficacy of anti-OPXV
therapeutics (Huggins et al., 2009) and vaccines (summa-
rized in Schmitt et al., 2014).
To mimic the natural route of infection, respiratory models
using MPXV, which often causes fibrinonecrotic bronchop-
neumonia that resembles the human MPXV and smallpox
disease course, were developed (Goff et al., 2011; Johnson
et al., 2011a; Zaucha et al., 2001). However, the work with
this animal model is complicated because of safety restric-
tions. The experiments must be performed in a biosafety level
(BSL)-3 containment facility. Furthermore, the VARV ani-
mal model, a suitable model for hemorrhagic smallpox used
in some drug efficacy studies (Huggins et al., 2009; Mucker
et al., 2013) as well as for pathogenesis studies (Wahl-Jensen
et al., 2011), is restricted to two BSL-4 laboratories world-
wide (Centers for Disease Control and Prevention, USA; and
State Research Center of Virology and Biotechnology, Rus-
sia). Thus, alternative models are needed, and those based on
CPXV, which is classified as a BSL-2 pathogen, are increas-
ing in interest.
CPXV has the broadest host range of all OPXV. Compared
to MPXV or VARV, research with CPXV can be done un-
der median safety conditions. Cynomolgus macaques have
been infected intravenously and intrabronchially with CPXV
to study pathogenesis (Johnson et al., 2011b; Smith et al.,
2012). Small-particle aerosol inoculation in rhesus macaques
resulted in a severe respiratory disease (Johnson et al., 2015).
Recently, we developed a nonhuman primate model based on
marmosets experimentally infected with the calpox virus that
belongs to the Cowpox virus species (Kramski et al., 2010).
Common marmosets are highly susceptible to the calpox
virus and they can be infected experimentally via an intra-
venous or intranasal (i.n.) route (Mätz-Rensing et al., 2006,
2012). The intranasal route of infection resembles the natural
infection route of smallpox and is therefore a suitable model
for the validation of therapeutics and vaccines. A disadvan-
tage of this model is that some species-specific reagents for
analyses are not available yet. The investigation of the im-
mune and the inflammatory response is especially impeded
as there is little knowledge on inflammatory markers in this
species. In contrast, a wide range of commercial systems to
investigate the inflammatory response and the cytokine and
chemokine profile in the rhesus monkey model is available.
We therefore wanted to investigate whether the fulminant
disease of marmosets following infection with the calpox
virus as described above can be reproduced in rhesus mon-
keys. If successful this could represent an alternative model
allowing for extended functional immunological studies on
orthopoxvirus pathogenesis. Based on the assumption that
older rhesus monkeys might be more susceptible to calpox
infection because of waning immune competence, we inocu-
lated aged monkeys with the calpox virus by the same routes
as described for marmosets (Kramski et al., 2010). Our re-
sults showed that, compared to marmosets, this species was
not only less susceptible to infection but, depending on the
route of inoculation, hardly developed severe clinical dis-
ease.
2 Materials and methods
2.1 Animals
Six healthy sexually mature female rhesus monkeys (Macaca
mulatta) belonging to the age category “aged macaques”
(Asquith et al., 2012) were obtained from the breeding
colony of the German Primate Center (see Table 1). The age
was between 19 and 23 years. Older monkeys were chosen
assuming that they were more susceptible to orthopoxvirus
infection than younger ones as reported for humans (Fen-
ner et al., 1989). During the experiments the animals were
housed in single cages with visual, olfactory and acoustic
contact to one another. They were allowed free access to
food and water and provided standard environmental en-
richment. All animals were adequately fed and cared for in
accordance with the German Animal Welfare act. The ani-
mal experiments were approved by the responsible veterinary
authorities (approval number: 33.14-42502-04-095/09) and
performed in accordance with the EU guidelines for the ac-
commodation and care of animals used for experimental and
other scientific purposes. Animals were clinically checked
twice a day. Blood samples were collected on days 4, 7, 10,
14, 17, 21 and at necropsy. Animals 2–6 were also sampled
on day 24 and 28. Animals that were moribund or terminally
ill were humanely euthanized using an overdose of barbitu-
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Table 1. Overview of inoculation route and clinical, pathohistological and virological findings.*
Animal Age Inoculation Clinical findings Pathohistologic Viral Development of
number (years) route, findings DNA in of OPXV-
volume, blood specific
and dose and/or antibodies
tissue
1 19 i.v., 1 mL, severe poxvirus- severe yes yes




2 23 i.v., 1 mL, poxvirus- Pneumonyssus yes yes
3.5 × 106 PFU induced skin pneumonia,
alterations leiomyoma of the
which healed uterus
3 21 i.n., 180 µL, three single Pneumonyssus no no







4 22 i.n., 180 µL, no poxvirus- Pneumonyssus no yes
7 × 105 PFU induced pneumonia,
alterations leiomyoma of the
uterus
5 20 i.n., 180 µL, no poxvirus- endometriosis, no yes
7 × 105 PFU induced leiomyoma of the
alterations uterus
6 23 i.n., 180 µL no poxvirus- endometriosis, no yes
7 × 105 PFU induced leiomyoma of the
alterations uterus
∗ i.v., intravenous; i.n., intranasal; PFU, plaque forming units.
rates. Severe apathy, weight loss, and inflammation of the
upper respiratory tract in combination with pox-like alter-
ations on skin and mucous membranes were the criteria used
to define terminally ill animals. Only animal 1 was eutha-
nized for animal welfare reasons at day 21 after infection. To
conclude the study, all remaining animals were euthanized
10 weeks after viral exposure. Complete post-mortem exam-
inations were performed on all animals. A comprehensive
organ spectrum was collected for histological, electron mi-
croscopical and virological analyses at necropsy.
2.2 Viral strain and application route
The calpox virus stock used for inoculation has been de-
scribed before (Kramski et al., 2010). The viral titer was
determined by plaque assay prior to its use in infection ex-
periments. The virus stock contained 3.5 × 106 PFU (plaque
forming units) mL−1.
The rhesus monkeys were infected intravenously with two
different infectious doses of the calpox virus (Table 1), de-
pending on the virus titer, the volume per ampoule (200 µL)
and overall availability of the stock. The first i.v. dose cor-
responded to 200 µL of undiluted virus. In order to po-
tentially augment clinical symptoms, the dose for the sec-
ond i.v. inoculated animal was increased fivefold. Since
whether intranasal inoculation would also lead to infection
of rhesus monkeys like in marmosets was unpredictable,
we chose undiluted virus for this route. For the purpose of
virus inoculation, monkeys were anesthetized by injecting
0.1 mL per 1 kg body weight of a mixture containing 5 % ke-
tamine, 1 % xylazine and 0.01 % atropine into the hamstring
muscles (Musculus semimembranosus, Musculus semitendi-
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nosus, Musculus biceps femoris). A volume of 1 mL calpox
virus was administered intravenously into the great saphe-
nous vein. For intranasal inoculation, three doses of 60 µL
of undiluted virus suspension were alternatingly applied into
the nostrils.
2.3 Isolation of total DNA from tissues and whole blood,
determination of viral genome equivalents and
infectious particles in saliva
Extraction of total DNA from tissue was performed in a Fast-
Prep apparatus (MP Biomedicals, Illkirch, France) with two
intervals of 20 s at 6 m s−1 for tissue homogenization as de-
scribed by Kramski et al. (2010). Nucleic acid was extracted
from lysate using the DNeasy Blood and Tissue Kit (Qiagen,
Hilden, Germany). DNA from whole blood was extracted us-
ing the DNA Blood Mini Kit (Qiagen, Hilden, Germany).
Extractions were performed according to the manufacturer’s
instructions, and DNA was eluted in 100 µL AE buffer (Qia-
gen). Quantification of viral genomes in purified DNA from
tissue or blood was amplified with a calpox-virus-specific
qPCR assay as reported (Kramski et al., 2010). Quantities of
viral DNA were expressed as genome equivalents (GE) per
mL of blood or for tissue samples per 106 copies of the c-myc
gene. To investigate oropharyngeal virus shedding, we ana-
lyzed saliva for the presence of infectious virus by a plaque
assay (Kramski et al., 2010).
2.4 Determination of binding and neutralizing antibodies
For the detection of binding antibodies an indirect ELISA
was performed (Miller et al., 2011), except that ELISA plates
were coated with 400 ng virus lysate per well prepared from
the calpox-virus-infected Hep2 cells by sonication and sub-
sequent centrifugation (5 min at 200 g). Plasma samples were
applied in a single 1 : 400 dilution, and for detection of
binding a HRP-coupled goat anti-human IgG antibody (In-
vitrogen, Karlsruhe, Germany) was used. Neutralizing anti-
bodies were determined by plaque reduction neutralization
test (PRNT) and the titer was calculated (Kramski et al.,
2010).
2.5 Histological examination
Samples for histopathology were immersion fixed in 10 %
neutral buffered formalin. Tissues underwent routine histo-
logical processing and immunohistological investigation as
previously published (Mätz-Rensing et al., 2012). Addition-
ally, selected sections of skin samples were processed for
transmission electron microscopy (TEM) after glutaralde-
hyde fixation (2.5 %) and embedding in Epon.
(a) (b)
(c) (d)
Figure 1. Dermal lesions at different time points after i.v. calpox
infection, Macaca mulatta, animal no. 2. (a) Focal umbilicated pus-
tular lesion beneath the nose, 17 days p.i. (arrows). (b) Severe focal
papular dermatitis of the left trigger finger, 17 days p.i. (arrows).
(c) Severe focal ulcerative dermatitis of the right arm induced by
confluent pustules, 17 days p.i. (arrows). (d) Severe focal ulcerative
dermatitis of the right arm covered by a crust, 21 days p.i. (arrows).
3 Results
3.1 Intravenous inoculation leading to vesiculopustular
rash
Two animals were inoculated by the intravenous route. Nu-
merous classical pox lesions started to develop on day 7 (an-
imal 1) and 10 (animal 2) post-inoculation. The first clini-
cal symptoms in both animals were exanthemas of the face
and the upper parts of the extremities as well as small sin-
gle macular lesions that appeared on the face, trunk and legs.
Macular lesions spread over the whole body and began to
develop into small papular and vesicular lesions. On day 10
and 12, pustules were spread over the entire body and began
to umbilicate. In addition, lesions occurred on oral and gen-
ital mucous membranes and the mucocutaneous junctions.
The lesions were completely umbilicated between day 14
and 17 (Fig. 1a). Moreover, the palms of hands and soles
of feet were affected. Here, umbilication of the lesions was
not observed (Fig. 1b). Lesions on the extremities tended to
coalesce (Fig. 1c). The maximal number and size of lesions
was observed at day 21 (approximately 50 for animal 1 and
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(a)
(b)
Figure 2. Detection of calpox DNA in blood and tissues of infected
animals. (a) At different time points post-infection (see materials
and methods), blood samples were taken, DNA was prepared from
whole blood and viral DNA was determined with a specific qPCR
assay. Genome equivalents (GE) for viral DNA were calculated per
mL of blood. (b) Viral load in tissue. Post-mortem samples from
various tissues were collected and DNA was isolated. Viral genome
equivalents were determined by q-PCR and correlated to 106 copies
of the c-myc gene.
140 for animal 2). In animal 1 the lesions reached diameters
of up to 3 cm, were highly confluent and became necrotic,
leading to a massive phlegmon of the right leg. This ani-
mal was immediately euthanized for animal welfare reasons
at day 21 post-infection (p.i.). In animal 2 the pox lesions
reached a maximal size of 1 cm in diameter, started to crust,
and became dry and flattened (Fig. 1d). Scabs developed and
fell off after about 4 weeks. After 5 weeks all lesions were
completely healed.
3.1.1 Viral load after intravenous inoculation
After intravenous infection, calpox virus DNA was first de-
tectable in blood between day 4 (animal 1) and 7 (animal 2).
In animal 1 viral DNA continuously increased until day 14
and reached a plateau with a maximum of 1.7 × 107 GE per
mL blood on day 21, just prior to its euthanization for an-
imal welfare reasons. In animal 2 the viral load peaked at
day 17 with 7.7 × 106 GE per mL blood and subsequently
gradually decreased by almost 2 orders of magnitude un-
til the analysis was stopped (Fig. 2a). Quantification of vi-
ral DNA in various tissues on the day of necropsy revealed
that in animal 1 (day 21 p.i.) calpox virus was present in
most of the investigated tissues (Fig. 2b). The highest vi-
ral load of 1.4 × 108 GE per 1 × 106 copies of c-myc was
observed in the skin of animal 1. Lower viral loads in the
range of 1.4 × 102 to 9.3 × 104 GE were measured in lym-
phatic, intestinal, mucosal, muscular and nervous tissues; in
the liver; and in the respiratory and reproductive organs. No
viral DNA was found in the heart, kidneys, adrenal glands,
bladder, small intestine, parotid gland or ovaries. In animal 2
(day 70 p.i. and after recovery) calpox virus PCR was clearly
positive in skin only (1.5 × 102 GE), with low-level detec-
tion in the parotid gland, bone marrow and spleen. The de-
tection of high copy numbers of viral DNA in many tissues
of animal 1 at the time of sacrifice as well as residual viral
DNA in some of the tissues in animal 2 after recovery in-
dicated a systemic infection of the rhesus monkeys infected
by the i.v. route (Fig. 2b). Saliva for the analysis of infec-
tious virus was available from animals 2–6. In animal 2 all
samples collected between day 4 and 24 were positive in the
plaque assay, indicating the presence of infectious virus in
saliva (Table 2).
3.1.2 Humoral immune responses
OPXV-specific binding antibodies were detectable by ELISA
in plasma of both animals (Fig. 3a). Animal 1 and 2 serocon-
verted between day 7 and 10, and antibody levels increased
until 3 weeks post-infection. As analyzed by PRNT, both in-
travenously infected animals started to develop neutralizing
antibodies against OPXV between day 7 and 10. Maximum
titers of 1 : 200 were observed between day 21 and 28 post-
infection.
3.1.3 Histologic investigation
Pathohistological investigation revealed typical poxvirus-
induced skin lesions in animal 1. The lesions were charac-
terized by superficial ulceration of the epidermis. The ul-
cerated parts were covered by a serocellular crust (Fig. 4a).
Adjacent parts of the epidermis showed irregular epidermal
hyperplasia and signs of acantholysis, acanthosis and syn-
cytia formation of the basal keratinocytes. Numerous large
Guarnieri bodies were found in altered epithelial cells. In
deeper parts of the dermis, follicular and sebaceous epithelia
were also affected, leading to severe chronic granulomatous
infection. The inflammatory infiltrate was predominated by
lymphocytes and histiocytes and extended deeply into der-
mis and subcutis. Characteristic intracytoplasmic inclusion
bodies were also found in enlarged vacuolated or degener-
ated cells of sebaceous glands (Fig. 4b). The Guarnieri bod-
ies measured 2–8 µm and were distributed randomly within
the altered epithelium. Animal 2 did not show pox-specific
alterations.
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oped neutralizing antibodies that appeared between day 14
and 21 after inoculation. Titers were generally lower in these
animals compared to the i.v. infected ones. Interestingly, in
one of these three animals (animal 6), neutralizing titers in-
creased continuously until the end of the follow-up (Fig. 3b).
4 Discussion
We previously showed that experimental low-dose intranasal
infection of common marmosets with the calpox virus re-
sults in fatal disease. The calpox virus belongs to the Cowpox
virus species and was isolated from Callithrix jacchus during
a natural outbreak of the disease in a private New World mon-
key husbandry (Mätz-Rensing et al., 2006). High doses of the
virus experimentally applied to marmosets reproducibly led
to death within 4 to 7 days. Even the intranasal application of
as low as 50 PFU of calpox virus to the New World monkeys
was infectious in 40 % of the animals and resulted in viremia
and fatal outcome (Kramski et al., 2010). The route and dose
used for viral inoculation of this monkey species mimics the
natural transmission of smallpox, thus representing a suitable
model to study pathogenesis and to evaluate new vaccines
and therapeutics against orthopoxvirus infection (Kramski et
al., 2010; Mätz-Rensing et al., 2012). However, this animal
model has some limitations due to the lack of species-specific
or cross-reactive reagents, particularly for the analysis of in-
nate immune responses which hamper certain experimental
approaches. The aim of the present study was to test whether
the results from the marmoset studies can be recapitulated in
rhesus macaques, a nonhuman primate species that has been
used in many different research fields for decades.
4.1 Rhesus macaques are less susceptible to calpox
virus exposure
The results of the study suggest that New World monkeys,
i.e., common marmosets, are more susceptible to the calpox
virus than rhesus monkeys. High levels of viral replication
were observed in blood accompanied by the appearance of
classical pox lesions of varying degree only when this Old
World monkey species was given high doses in the range
of 106 PFU of infectious virus intravenously. A comparable
dose applied to marmosets reproducibly led to death within
4 to 7 days (Kramski et al., 2010). A dose of 8.3 × 103 PFU
reliably led to infection and 100 % mortality in marmosets
(Mätz-Rensing et al., 2012), while an approximately 100-
fold higher dose of calpox virus inoculated intranasally in
rhesus monkeys compared to that used in marmosets was not
sufficient to induce viremia, let alone conspicuous clinical
alterations. Nonetheless, seroconversion in three out of four
rhesus monkeys inoculated intranasally and the detection of
infectious virus in saliva of two of the three seroconverted an-
imals suggest local low-level replication, presumably at the
portal of virus entry, which could be the nasal epithelium.
Those findings can be defined as subclinical infection.
4.2 Symptomatic infection requires high virus doses
In contrast to marmosets, a very high dose of calpox virus is
needed to infect rhesus macaques. Nevertheless, the clinical
symptoms observed in the rhesus macaques infected intra-
venously were typical of an orthopoxvirus infection. Both
animals developed viremia followed by characteristic skin
lesions. Whereas the lesions in animal 1 showed similari-
ties with the confluent ordinary smallpox type with a higher
fatality rate, lesions in animal 2 could be compared with a
mild discrete ordinary type of smallpox. In both animals,
the pustules on the face, arms and extremities were numer-
ous and rather sparse on the trunk. Lesions were all at the
same stage; those that appeared earliest on face and upper
extremities were more mature than those that appeared later
on other parts of the body. Lesions were also present on soles
and palms. Except on soles and palms, umbilication was a
common feature of the skin lesions similar to smallpox dis-
ease. Histological analyses demonstrated that cells of the se-
baceous glands were highly susceptible, which is typical of
the infection with other cowpox viruses or smallpox.
Furthermore, the older age of the monkeys in this study
should be considered. Upon necropsy, all animals presented
with minor chronic diseases, such as pulmonary acariasis in-
duced by Pneumonyssus semicola or endometriosis (see Ta-
ble 1), which often represent clinically inapparent lesions
in older animals. This could lead to the assumption that
these clinically inapparent diseases as well as the old age of
the monkeys might have affected their ability to resist the
viruses, making them more susceptible to the administered
calpox virus. In humans, children and elderly people seem to
be more vulnerable to orthopoxvirus infections than middle-
aged people (Fenner et al., 1989). However, this does not
seem to be the case with the calpox virus in rhesus macaques.
Apparently, old age does not seem to increase the suscepti-
bility to this virus. Intranasally infected rhesus monkeys re-
mained healthy, and animals infected by the i.v. route devel-
oped relatively moderate symptoms in relation to the high
viral dose that was inoculated. This confirms that the calpox
virus is less pathogenic to macaques compared to marmosets
and leads to the question of species-specific pathogenicity
that seems to be a phenomenon of CPXV.
4.3 Species-specific pathogenicity and host range
phenomena
Despite high genetic homology, OPXV shows great differ-
ences in host range. On the one hand, VARV, which is re-
stricted to humans, has no known natural reservoir and is less
pathogenic to nonhuman primates. On the other hand, CPXV
with a known reservoir in rodents has a broad host range
and is responsible for lethal CPXV infections in different an-
imal species and even humans (Essbauer et al., 2010; Eis-
Hübinger et al., 1990). The combination of the CPXV strain
and host seems to play an important role in pathogenesis and
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disease outcome. A CPXV infection in humans or cats usu-
ally leads to a self-limiting local infection, while the same
virus strain induces death in susceptible animal species as
described for banded mongooses and jaguarundis (Kurth et
al., 2009). Similar observations were made for other CPXV–
host combinations (Kurth et al., 2008). It could be shown
that the calpox virus also belonging to the CPXV species
led to highly reproducible lethal disease in marmosets but
was less pathogenic in mice (unpublished data). The results
of the present study demonstrated a lower pathogenicity of
the same virus for Old World monkeys and underline the
great influence of virus–host interrelationships for disease
outcome. The molecular factors which determine the host
range and host-specific pathogenicity are not very well un-
derstood yet. Taking all these facts into account, it could
be assumed that the cowpox virus, which represents an Old
World virus, has a higher virulence for New World species
such as marmosets, jaguarundis or prairie dogs.
4.4 Susceptibility of macaques to other CPXV strains
The observation that the calpox virus is less pathogenic to
rhesus macaques led to the question whether Old World mon-
keys are susceptible to CPXV in general. During a natural
cowpox outbreak in a sanctuary for exotic animals in the
Netherlands, several animals of different macaque species
developed neutralizing serum antibody titers, indicating an
exposure to the virus, but only three of them developed mild
clinical symptoms. Experience of this outbreak suggests that
macaques are susceptible to cowpox virus but that the clinical
outcome is less severe than in New World monkeys (Mar-
tina et al., 2006; Mätz-Rensing et al., 2006). There is evi-
dence that cynomolgus and rhesus macaques are susceptible
to CPXV Brighton Red (CPXV-BR). Recently, 14 cynomol-
gus macaques were inoculated intravenously with different
doses of CPXV Brighton Red (5 × 104 − 5 × 107 − PFU;
Johnson et al., 2011b). A total of 9 out of 14 animals de-
veloped typical pox-like skin lesions. Further findings in-
cluded hemorrhages in a variety of organs, indicating a hem-
orrhagic course of disease. Infection was uniformly lethal
within 12 days post-inoculation. The researchers concluded
that this animal model may serve as a model for hemor-
rhagic smallpox, which is more feasible than the VARV
model (Jahrling et al., 2004). The same researchers adapted
a method of the intrabronchial and intra-alveolar infection
with CPXV-BR to mimic the natural route of infection more
closely. Intrabronchial inoculation and small-particle aerosol
inoculation of cowpox BR led to a severe respiratory dis-
ease in both macaque species (Smith et al., 2012; Johnson et
al., 2015). Macaques inoculated by aerosol developed severe
bronchointerstitial necrotizing pneumonia, but skin lesions
were not observed and the viral dissemination was limited.
This shows that the route of infection strongly influences dis-
ease progression.
5 Conclusion
Rhesus macaques are less susceptible to calpox virus expo-
sure. Symptomatic infection requires high virus doses and
depends on the route of application. Therefore, the rhesus
monkey calpox model is not suited for calpox virus re-
search and is of limited use in further intervention studies
against OPXV.
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